Workplace Mental Health: Consultation on the evidence (21st February 2008)
NICE was asked by the Department of Health (DH) to develop guidance for employers on promoting mental wellbeing through productive and healthy working conditions. All registered stakeholders for the NICE public health intervention guidance on Workplace Mental Health are invited to comment on the draft summary of evidence to inform the development of the guidance. This is the evidence collated by NICE so far. This will be used by the Institute's public health intervention advisory committee (PHIAC) to develop its recommendations. Closing date for comments is 20th March 2008.
Click here for the Synopsis of the Evidence
Click here for the Comments Form
Anaemia (cancer-treatment induced) – erythropoietin (alpha and beta) and darbepoetin: final appraisal determination (25th February 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Please note that the appeal period for this appraisal will close at 5pm on 7 March 2008.
Click here for the Final Appraisal Determination
Click here for the Consultee and commentator comments
NICE was asked by the Department of Health (DH) to develop guidance for employers on promoting mental wellbeing through productive and healthy working conditions. All registered stakeholders for the NICE public health intervention guidance on Workplace Mental Health are invited to comment on the draft summary of evidence to inform the development of the guidance. This is the evidence collated by NICE so far. This will be used by the Institute's public health intervention advisory committee (PHIAC) to develop its recommendations. Closing date for comments is 20th March 2008.
Click here for the Synopsis of the Evidence
Click here for the Comments Form
Anaemia (cancer-treatment induced) – erythropoietin (alpha and beta) and darbepoetin: final appraisal determination (25th February 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Erythropoetin (alpha and beta) and darbepoetin for the treatment of cancer-treatment induced anaemia and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Please note that the appeal period for this appraisal will close at 5pm on 7 March 2008.
Click here for the Final Appraisal Determination
Click here for the Consultee and commentator comments
Click here for the Response to consultee, commentator and public comments
Atypical psychosis (first onset) – neuro-imaging. Technical appraisal Guidance TA136 (27th February 2008)
Structural neuroimaging, using methods called magnetic resonance imaging (MRI) or computed axial tomography (CT) scanning, is not recommended for use routinely to examine all people who have had a first episode of psychosis.
Click here for the Guidance
Click here for the Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for the Costing Statement
Community Engagement. Public Health Programme Guidance PH009 (27th February 2008)
This guidance aims to support those working with and involving communities in decisions on health improvement that affect them. It is for people working in the NHS and other sectors who have a direct or indirect role in - and responsibility for - community engagement. This includes those working in local authorities and the community, voluntary and private sectors. It will also be of interest to members of the public.
Click here for the Guidance
Click here for the Quick Reference Guide
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal masses. Intervention Procedure Guidance IPG254 (27th February 2008)
This procedure can be used for patients who are being tested for various diseases, including lung cancer. Under local or general anaesthesia, a thin flexible telescope (bronchoscope) is inserted via the patient's mouth into the lungs. Images of the region between the two lungs (the mediastinum) are obtained using an ultrasound probe attached to the bronchoscope. The operator uses these images as a guide when taking samples of cells from masses suspected of disease. The aim of the procedure is to help reach a diagnosis and establish whether the disease has spread.
Click here for the Full Guidance
Click here for the Understanding NICE Guidance
Click here for the Consultation Comments Table
Irritable Bowel Syndrome. Clinical Guideline CG61 (27th February 2008)
The advice in the NICE guideline covers the care of adults with irritable bowel syndrome, including: the support, treatment and advice people should be offered by their GP in diagnosing and helping to manage their irritable bowel syndrome; circumstances when people need to be referred to a specialist for further tests. It does not specifically look at: iirritable bowel syndrome in children and young people under 18 years; people with other gastrointestinal disorders such as non-ulcer dyspepsia (indigestion with no obvious cause) or coeliac disease.
Click here for NICE Guideline
Click here for Quick Reference Guide
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Click here for the Costing Report
Laparoscopic mobilisation of the greater omentum for breast reconstruction. Intervention Procedure Guidance IPG253 (27th February 2008)
Breast reconstruction surgery is carried out to try and restore the shape of the breast after surgery to remove part of or the whole breast. The omentum is a sheet of fat attached to the stomach, which can be moved to the breast cavity by tunnelling it under the skin (it stays attached to its original blood supply). In this procedure, the omentum is mobilised using 'keyhole' surgery.
Click here for the Guidance
Click here for the Understanding NICE Guidance
Click here for the Consultee Comments Table
Laser-assisted non-occlusive cerebral vascular anastomosis without temporary arterial occlusion. Intervention Procedure Guidance IPG252 (27th February 2008)
Arteries in the head may need to be bypassed as part of an operation, usually because of 'ballooning' or blockage of arteries. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion aims to create a bypass without the need to temporarily interrupt the blood flow to the brain.
Click here for the Guidance
Click here for the Understanding NICE Guidance
Click here for the Audit Criteria
Liposuction for chronic lymphoedema. Intervention Procedure Guidance IPG251 (27th February 2008)
Chronic lymphoedema is swelling of the limb caused by a defect in the lymphatic system. This may be a defect that the patient is born with or can result from surgical removal of the lymph glands, such as in surgery for breast cancer. The swelling results from accumulation of lymph fluid and it can cause cosmetic problems, discomfort, pain and limited movement. Liposuction for chronic lymphoedema involves the removal of subcutaneous adipose tissue and accumulated lymph fluid via several small incisions in the limb. After the procedure, the patient wears a compression garment permanently, which can be removed intermittently for short periods.
Click here for the Guidance
Click here for the Understanding NICE Guidance
Click here for the Consultee Comments Table
Click here for the Audit Criteria
Lymphoma (follicular non-Hodgkin's) – rituximab. Technology Appraisal Guidance TA137 (27th February 2008)
This guidance replaces NICE technology appraisal guidance 37 issued in March 2002. The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.
Click here for the Guidance
Click here for the Quick Reference Guide
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Atypical psychosis (first onset) – neuro-imaging. Technical appraisal Guidance TA136 (27th February 2008)
Structural neuroimaging, using methods called magnetic resonance imaging (MRI) or computed axial tomography (CT) scanning, is not recommended for use routinely to examine all people who have had a first episode of psychosis.
Click here for the Guidance
Click here for the Quick Reference Guide
Click here for Understanding NICE Guidance
Click here for the Costing Statement
Community Engagement. Public Health Programme Guidance PH009 (27th February 2008)
This guidance aims to support those working with and involving communities in decisions on health improvement that affect them. It is for people working in the NHS and other sectors who have a direct or indirect role in - and responsibility for - community engagement. This includes those working in local authorities and the community, voluntary and private sectors. It will also be of interest to members of the public.
Click here for the Guidance
Click here for the Quick Reference Guide
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal masses. Intervention Procedure Guidance IPG254 (27th February 2008)
This procedure can be used for patients who are being tested for various diseases, including lung cancer. Under local or general anaesthesia, a thin flexible telescope (bronchoscope) is inserted via the patient's mouth into the lungs. Images of the region between the two lungs (the mediastinum) are obtained using an ultrasound probe attached to the bronchoscope. The operator uses these images as a guide when taking samples of cells from masses suspected of disease. The aim of the procedure is to help reach a diagnosis and establish whether the disease has spread.
Click here for the Full Guidance
Click here for the Understanding NICE Guidance
Click here for the Consultation Comments Table
Irritable Bowel Syndrome. Clinical Guideline CG61 (27th February 2008)
The advice in the NICE guideline covers the care of adults with irritable bowel syndrome, including: the support, treatment and advice people should be offered by their GP in diagnosing and helping to manage their irritable bowel syndrome; circumstances when people need to be referred to a specialist for further tests. It does not specifically look at: iirritable bowel syndrome in children and young people under 18 years; people with other gastrointestinal disorders such as non-ulcer dyspepsia (indigestion with no obvious cause) or coeliac disease.
Click here for NICE Guideline
Click here for Quick Reference Guide
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Click here for the Costing Report
Laparoscopic mobilisation of the greater omentum for breast reconstruction. Intervention Procedure Guidance IPG253 (27th February 2008)
Breast reconstruction surgery is carried out to try and restore the shape of the breast after surgery to remove part of or the whole breast. The omentum is a sheet of fat attached to the stomach, which can be moved to the breast cavity by tunnelling it under the skin (it stays attached to its original blood supply). In this procedure, the omentum is mobilised using 'keyhole' surgery.
Click here for the Guidance
Click here for the Understanding NICE Guidance
Click here for the Consultee Comments Table
Laser-assisted non-occlusive cerebral vascular anastomosis without temporary arterial occlusion. Intervention Procedure Guidance IPG252 (27th February 2008)
Arteries in the head may need to be bypassed as part of an operation, usually because of 'ballooning' or blockage of arteries. Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion aims to create a bypass without the need to temporarily interrupt the blood flow to the brain.
Click here for the Guidance
Click here for the Understanding NICE Guidance
Click here for the Audit Criteria
Liposuction for chronic lymphoedema. Intervention Procedure Guidance IPG251 (27th February 2008)
Chronic lymphoedema is swelling of the limb caused by a defect in the lymphatic system. This may be a defect that the patient is born with or can result from surgical removal of the lymph glands, such as in surgery for breast cancer. The swelling results from accumulation of lymph fluid and it can cause cosmetic problems, discomfort, pain and limited movement. Liposuction for chronic lymphoedema involves the removal of subcutaneous adipose tissue and accumulated lymph fluid via several small incisions in the limb. After the procedure, the patient wears a compression garment permanently, which can be removed intermittently for short periods.
Click here for the Guidance
Click here for the Understanding NICE Guidance
Click here for the Consultee Comments Table
Click here for the Audit Criteria
Lymphoma (follicular non-Hodgkin's) – rituximab. Technology Appraisal Guidance TA137 (27th February 2008)
This guidance replaces NICE technology appraisal guidance 37 issued in March 2002. The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted.
Click here for the Guidance
Click here for the Quick Reference Guide
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Osteoarthritis. Clinical Guideline CG59 (27th February 2008)
The advice in the NICE guideline covers the treatment, advice and support that people who have osteoarthritis should be offered by their healthcare professional and when being referred to specialist care. This includes: diagnosis; education; exercise and physiotherapy; medicines; alternative therapies; surgery. It does not specifically look at the care and management of related conditions (for example, rheumatoid arthritis and joint pain).
Click here for the NICE Guideline
Click here for the Quick Reference Guide
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Click here for the Costing Report
Prostate Cancer. Clinical Guideline CG58 (27th February 2008)
This guideline covers the tests, treatment, care and support that men who have suspected or diagnosed prostate cancer should be offered. It does not specifically look at the care of men with rare cancers of the prostate (for example, small-cell carcinoma and rhabdomyosarcoma).
Click here for the Full Guidance
Click here for the NICE Guidance
Click here for the Quick Reference Guide
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Click here for the Costing Report
Smoking Cessation. Public Health Intervention Guidance PHI001 (27th February 2008)
The NICE public health intervention guidance on brief interventions and referral for smoking cessation in primary care and other settings guidance considers whether brief smoking cessation interventions are effective at encouraging individuals to quit smoking. The impact of wider policy and practice on smoking cessation will be the subject of future NICE programme guidance.
Click here for the Guidance
Click here for the Quick Reference Guide (Professionals)
Click here for the Quick Reference Guide (Public)
Click here for the Costing Template
Click here for the Costing Report
Click here for the Audit Criteria
Click here for the Implementation Advice
Surgical management of Otitis Media with Effusion (OME). Clinical Guideline CG60 (27th February 2008)
The advice in the NICE guideline covers: the surgical management of OME in children younger than 12 years; guidance for managing OME in children with Down's syndrome and in children with all types of cleft palate. It does not specifically look at the management of OME in: children with other syndromes (for example, craniofacial dysmorphism or polysaccharide storage disease); children with multiple complex needs.
Click here for the Full Guideline
Click here for the NICE Guideline
Click here for the Quick Reference Guide
Click here for the Search Strategies
Click here for the Excluded Studies
Click here for the Evidence Tables
Click here for the Understanding NICE Guidance
Click here for the Costing Template
Click here for the Costing Report
No comments:
Post a Comment